Edition:
United Kingdom

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

12:40am GMT

Primitive art: Neanderthals were Europe's first painters

LONDON The world's oldest known cave paintings were made by Neanderthals, not modern humans, suggesting our extinct cousins were far from being uncultured brutes.

22 Feb 2018

Novo's pioneering diabetes pill impresses in first big study

COPENHAGEN/LONDON The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.

21 Feb 2018

Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co , already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.

19 Feb 2018

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

15 Feb 2018

Indivior bets on $1 billion anti-addiction shot as legal bill weighs

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

13 Feb 2018

Drug copies ready to take next bite out of Roche's cancer sales

LONDON European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.

08 Feb 2018

Reckitt, GSK balance risk-reward in high-stakes Pfizer fight

LONDON The leaders of GlaxoSmithKline and Reckitt Benckiser -- two of Britain's best-known but underperforming companies -- are in a high-stakes battle for a dose of Advil to ease their pain.

08 Feb 2018

Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

LONDON GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division.

07 Feb 2018

GlaxoSmithKline sees light at end of Advair tunnel

LONDON GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year.

06 Feb 2018

In diabetes war, Novo Nordisk aims to break mold with new pill

LONDON After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,252.39 -29.18 -0.40%
DAX 12,461.91 -- --%
CAC 40 5,309.23 + 0.00 +0.00%
TR Europe 189.57 -0.06 -0.03%
GBP/USD 1.3946 -0.06%
GBP/EUR 1.1335 +0.14%
EUR/USD 1.2300 -0.24%
Gold 1,330.60 +0.00 +0.00%
Oil 62.75 -0.02 -0.03%
Corn 367.25 +0.50 +0.14%